VRAX
Virax Biolabs Group Limited
Price Chart
Latest Quote
$3.45
-0.29 (-7.75%)
Current Price
| Previous Close | $3.74 |
| Open | $3.70 |
| Day High | $3.71 |
| Day Low | $3.32 |
| Volume | 138,248 |
Stock Information
| Shares Outstanding | 797K |
| Total Debt | $414K |
| Cash Equivalents | $6.52M |
| Revenue | $12K |
| Net Income | $-5.02M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $3.02M |
| EPS (TTM) | $-12.28 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-4.15M |
| Sales | $12K |
| Income | $-5.02M |
| Book/sh | $13.08 |
| Cash/sh | $8.18 |
| Employees | 26 |
Financial Ratios
| Quick Ratio | 9.55 |
| Current Ratio | 9.97 |
| Debt/Eq | 5.65 |
Returns & Margins
| ROA | -54.23% |
| ROE | -78.65% |
| Gross Margin | 61.90% |
| Operating Margin | -35264.92% |
Ownership
| Insider Ownership | 2.62% |
| Institutional Ownership | 4.61% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.63 |
| P/S | 243.14 |
| P/B | 0.29 |
Analyst Data
| Recommendation | none |
| Target Price | $25.00 |
Technical Indicators
| SMA20 | $3.64 |
| SMA50 | $4.43 |
| SMA200 | $7.56 |
| RSI | 54.28 |
| ATR | 1.3250 |
| Shares Float | 529K |
| Short Float | 7.78% |
| Short Ratio | 0.33 |
| Volatility | 1.33 |
| Rel Volume | 0.09 |
Performance History
| Week | -7.11% |
| Month | -3.44% |
| Quarter | -0.26% |
| 6 Months | -54.47% |
| YTD | -60.52% |
| Year | -83.54% |
| 3 Years | -96.11% |
| 10 Years | -99.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $3.79 | 405,100 |
| 2026-07-16 | $3.90 | 12,552,500 |
| 2026-07-15 | $3.45 | 141,200 |
| 2026-07-14 | $3.74 | 251,800 |
| 2026-07-13 | $4.07 | 986,600 |
| 2026-07-10 | $4.08 | 1,754,400 |
| 2026-07-09 | $6.36 | 72,005,300 |
| 2026-07-08 | $3.18 | 38,400 |
| 2026-07-07 | $3.04 | 116,000 |
| 2026-07-06 | $3.11 | 82,300 |
| 2026-07-02 | $3.13 | 244,100 |
| 2026-07-01 | $2.74 | 1,305,300 |
| 2026-06-30 | $2.94 | 77,300 |
| 2026-06-29 | $3.26 | 416,500 |
| 2026-06-26 | $3.11 | 675,900 |
| 2026-06-25 | $3.38 | 32,840 |
| 2026-06-24 | $3.30 | 92,076 |
| 2026-06-23 | $3.88 | 19,616 |
| 2026-06-22 | $4.07 | 22,728 |
| 2026-06-18 | $4.32 | 41,244 |
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, focuses on immune response detection, T cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated diseases in the United Kingdom, the United States, and China. The company offers ViraxImmune, a T cell-based immune profiling and diagnostic platform for post-acute infection syndromes, including long COVID, myalgic encephalomyelitis / chronic fatigue syndrome, and post-treatment Lyme disease. It also provides ImmuneSelect, a research-use-only portfolio of peptide pool ELISpot plates and related immune reagents. In addition, the company is involved in research and development activities and the provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, academic institutions, contract research organizations, biopharmaceutical companies, independent laboratories, and distributors. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, United Kingdom.
đ° Latest News
Virax Biolabs enters immune profiling product supply deal with Fosun
Hospital Management âĸ 2026-07-13T09:48:28Z
Why Did Virax Biolabs Stock Triple In One Session?
Benzinga âĸ 2026-07-09T14:31:31Z
Virax Biolabs Shares Double After Exclusive Fosun Distribution Agreement (VRAX)
InvestorsHub âĸ 2026-07-09T14:06:41Z
Virax Biolabs Group Limited (VRAX) Upgraded to Buy: Here's Why
Zacks âĸ 2026-01-15T17:00:02Z
BC-Most Active Stocks
Associated Press Finance âĸ 2025-12-03T15:30:18ZVirax Biolabs (VRAX) Falls 18% on Lack of Leads
Insider Monkey âĸ 2025-08-27T16:05:35Z
EXCLUSIVE: Virax Biolabs Inks Research Pact To Advance Long COVID Diagnostic Studies
Benzinga âĸ 2025-08-26T11:15:26Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,733 | $59,398 | $105,829 | $9,926 |
| Cost Of Revenue | $4,733 | $59,398 | $105,829 | $9,926 |
| Total Revenue | $12,423 | $6,331 | $156,419 | $8,561 |
| Operating Revenue | $12,423 | $6,331 | $156,419 | $8,561 |
| Expenses | ||||
| Interest Expense | $61,772 | $58,179 | $26,878 | $15,468 |
| Total Expenses | $6,412,153 | $6,083,133 | $6,291,744 | $5,741,322 |
| Other Income Expense | $529,078 | $-68,912 | $-576,917 | $290,466 |
| Other Non Operating Income Expenses | $33 | $17,183 | $-215,769 | $290,466 |
| Net Non Operating Interest Income Expense | $-61,772 | $-58,179 | $-26,878 | $-15,468 |
| Interest Expense Non Operating | $61,772 | $58,179 | $26,878 | $15,468 |
| Operating Expense | $6,407,420 | $6,023,735 | $6,185,915 | $5,731,396 |
| General And Administrative Expense | $2,669,062 | $3,992,400 | $4,571,279 | $3,552,055 |
| Selling And Marketing Expense | - | - | - | $26,616 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-5,023,750 | $-6,061,247 | $-6,733,537 | $-5,457,494 |
| Net Interest Income | $-61,772 | $-58,179 | $-26,878 | $-15,468 |
| Normalized Income | $-5,472,513 | $-5,977,049 | $-6,372,389 | $-5,457,494 |
| Net Income From Continuing And Discontinued Operation | $-5,023,750 | $-6,061,247 | $-6,733,537 | $-5,457,494 |
| Total Operating Income As Reported | $-6,399,730 | $-6,076,802 | $-6,525,680 | $-5,732,761 |
| Net Income Common Stockholders | $-5,023,750 | $-6,061,247 | $-6,733,537 | $-5,457,494 |
| Net Income | $-5,023,750 | $-6,061,247 | $-6,733,537 | $-5,457,494 |
| Net Income Including Noncontrolling Interests | $-5,032,184 | $-6,067,232 | $-6,739,120 | $-5,457,763 |
| Net Income Continuous Operations | $-5,032,184 | $-6,067,232 | $-6,739,120 | $-5,457,763 |
| Pretax Income | $-5,932,424 | $-6,203,893 | $-6,739,120 | $-5,457,763 |
| Special Income Charges | $0 | $0 | $-390,355 | $0 |
| Operating Income | $-6,399,730 | $-6,076,802 | $-6,135,325 | $-5,732,761 |
| Gross Profit | $7,690 | $-53,067 | $50,590 | $-1,365 |
| Per Share | ||||
| Diluted EPS | $-12.64 | $-40.62 | $-83.90 | $-128.25 |
| Basic EPS | $-12.64 | $-40.62 | $-83.90 | $-128.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $80,282 | $-1,897 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,960,679 | $-5,716,232 | $-6,247,995 | $-5,442,295 |
| Total Unusual Items | $529,045 | $-86,095 | $-361,148 | $0 |
| Total Unusual Items Excluding Goodwill | $529,045 | $-86,095 | $-361,148 | $0 |
| Reconciled Depreciation | $439,018 | $343,387 | $103,099 | $0 |
| EBITDA (Bullshit earnings) | $-5,431,634 | $-5,802,327 | $-6,609,143 | $-5,442,295 |
| EBIT | $-5,870,652 | $-6,145,714 | $-6,712,242 | $-5,442,295 |
| Diluted Average Shares | $397,590 | $149,214 | $80,257 | $42,519 |
| Basic Average Shares | $397,590 | $149,214 | $80,257 | $42,519 |
| Diluted NI Availto Com Stockholders | $-5,023,750 | $-6,061,247 | $-6,733,537 | $-5,457,494 |
| Minority Interests | $8,434 | $5,985 | $5,583 | $269 |
| Tax Provision | $-900,240 | $-136,661 | $0 | $0 |
| Impairment Of Capital Assets | $0 | $0 | $390,355 | $0 |
| Gain On Sale Of Security | $529,045 | $-86,095 | $29,207 | - |
| Research And Development | $3,738,358 | $2,031,335 | $1,614,636 | $2,179,341 |
| Selling General And Administration | $2,669,062 | $3,992,400 | $4,571,279 | $3,552,055 |
| Other Gand A | $2,669,062 | $3,992,400 | $4,571,279 | $3,552,055 |
Fetched: 2026-07-16
Balance Sheet (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $7,577,341 | $5,696,120 | $5,366,757 | $8,948,011 |
| Total Assets | $8,324,772 | $6,426,903 | $5,483,969 | $9,812,416 |
| Total Non Current Assets | $1,496,174 | $1,533,248 | $1,103,717 | $178,403 |
| Current Assets | $6,828,598 | $4,893,655 | $4,380,252 | $9,634,013 |
| Prepaid Assets | $362,577 | $539,382 | $512,782 | $281,475 |
| Inventory | $0 | $94,675 | $60,383 | $0 |
| Receivables | $27,112 | $30,654 | $217,843 | $0 |
| Taxes Receivable | $27,112 | $30,654 | $217,843 | $0 |
| Cash Cash Equivalents And Short Term Investments | $6,438,909 | $4,228,944 | $3,589,244 | $9,352,538 |
| Cash And Cash Equivalents | $6,438,909 | $4,228,944 | $3,589,244 | $9,352,538 |
| Cash Financial | $6,438,909 | $4,228,944 | $3,589,244 | $9,352,538 |
| Goodwill And Other Intangible Assets | - | - | $0 | $178,403 |
| Other Intangible Assets | - | - | - | $178,403 |
| Accounts Receivable | - | - | - | - |
| Allowance For Doubtful Accounts Receivable | - | - | - | - |
| Gross Accounts Receivable | - | - | - | - |
| Debt | ||||
| Total Debt | $414,387 | $377,004 | $224,300 | $146,250 |
| Long Term Debt And Capital Lease Obligation | $304,808 | $291,543 | $176,345 | $0 |
| Current Debt And Capital Lease Obligation | $109,579 | $85,461 | $47,955 | $146,250 |
| Current Debt | $28,477 | $32,468 | - | $146,250 |
| Other Current Borrowings | $28,477 | $32,468 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $989,832 | $964,750 | $345,194 | $908,401 |
| Total Non Current Liabilities Net Minority Interest | $304,808 | $291,543 | $176,345 | $0 |
| Current Liabilities | $685,024 | $673,207 | $168,849 | $908,401 |
| Payables And Accrued Expenses | $490,401 | $527,261 | $120,894 | $314,195 |
| Payables | $332,739 | $400,718 | $57,774 | $192,204 |
| Total Tax Payable | $14,991 | $7,049 | $12,143 | $14,000 |
| Accounts Payable | $51,766 | $56,093 | $45,631 | $159,908 |
| Current Deferred Liabilities | - | - | $0 | $38,250 |
| Current Notes Payable | - | - | $0 | $146,250 |
| Equity | ||||
| Common Stock Equity | $7,577,341 | $5,696,120 | $5,366,757 | $9,126,414 |
| Total Equity Gross Minority Interest | $7,334,940 | $5,462,153 | $5,138,775 | $8,904,015 |
| Stockholders Equity | $7,577,341 | $5,696,120 | $5,366,757 | $9,126,414 |
| Gains Losses Not Affecting Retained Earnings | $37,175,855 | $30,281,022 | $23,892,180 | $20,919,317 |
| Other Equity Adjustments | $37,175,855 | $30,281,022 | $23,892,180 | $20,919,317 |
| Retained Earnings | $-29,612,994 | $-24,589,244 | $-18,527,997 | $-11,794,460 |
| Other Equity Interest | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $579,218 | $173,678 | $102,956 | $62,188 |
| Share Issued | $579,218 | $173,678 | $102,956 | $62,188 |
| Tangible Book Value | $7,577,341 | $5,696,120 | $5,366,757 | $8,948,011 |
| Invested Capital | $7,605,818 | $5,728,588 | $5,366,757 | $9,272,664 |
| Working Capital | $6,143,574 | $4,220,448 | $4,211,403 | $8,725,612 |
| Capital Lease Obligations | $385,910 | $344,536 | $224,300 | $0 |
| Total Capitalization | $7,577,341 | $5,696,120 | $5,366,757 | $9,126,414 |
| Minority Interest | $-242,401 | $-233,967 | $-227,982 | $-222,399 |
| Capital Stock | $14,480 | $4,342 | $2,574 | $1,557 |
| Common Stock | $14,480 | $4,342 | $2,574 | $1,557 |
| Long Term Capital Lease Obligation | $304,808 | $291,543 | $176,345 | $0 |
| Current Capital Lease Obligation | $81,102 | $52,993 | $47,955 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $85,044 | $60,485 | $0 | $409,706 |
| Current Accrued Expenses | $157,662 | $126,543 | $63,120 | $121,991 |
| Dueto Related Parties Current | $265,982 | $337,576 | $0 | $18,296 |
| Net PPE | $1,496,174 | $1,533,248 | $1,103,717 | $0 |
| Accumulated Depreciation | $-938,955 | $-442,306 | $-103,099 | $-11,104 |
| Gross PPE | $2,435,129 | $1,975,554 | $1,206,816 | $11,104 |
| Other Properties | $2,352,325 | $1,904,789 | $1,145,186 | - |
| Machinery Furniture Equipment | $82,804 | $70,765 | $61,630 | $11,104 |
| Finished Goods | $-94,675 | $0 | $60,383 | $0 |
| Work In Process | $44,719 | $44,719 | $0 | - |
| Raw Materials | $49,956 | $49,956 | $0 | - |
| Current Deferred Revenue | - | - | $0 | $38,250 |
Fetched: 2026-07-16
Cash Flow Statement (Annual)
| Metric | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-4,877,723 | $-5,167,466 | $-7,561,371 | $-4,358,170 |
| Operating Activities | ||||
| Operating Cash Flow | $-4,621,892 | $-4,563,576 | $-6,396,922 | $-4,179,767 |
| Cash Flow From Continuing Operating Activities | $-4,621,892 | $-4,563,576 | $-6,396,922 | $-4,179,767 |
| Operating Gains Losses | $-469,740 | $123,743 | $-8,797 | $-294,272 |
| Investing Activities | ||||
| Capital Expenditure | $-255,831 | $-603,890 | $-1,164,449 | $-178,403 |
| Investing Cash Flow | $-255,831 | $-603,890 | $-1,164,449 | $-178,403 |
| Cash Flow From Continuing Investing Activities | $-255,831 | $-603,890 | $-1,164,449 | $-178,403 |
| Financing Activities | ||||
| Financing Cash Flow | $7,087,688 | $5,807,166 | $1,798,077 | $13,688,952 |
| Cash Flow From Continuing Financing Activities | $7,087,688 | $5,807,166 | $1,798,077 | $13,688,952 |
| Net Other Financing Charges | $4,413,758 | - | $-18,296 | $-111,645 |
| Issuance Of Capital Stock | - | $5,128,186 | $234 | $13,654,347 |
| Net Common Stock Issuance | - | $5,128,186 | $234 | $13,654,347 |
| Common Stock Issuance | - | $5,128,186 | $234 | $13,654,347 |
| Other | ||||
| Repayment Of Debt | $-109,482 | $-107,756 | $-56,366 | $-341,250 |
| Interest Paid Supplemental Data | $40,998 | $78,953 | $6,104 | $15,468 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $6,438,909 | $4,228,944 | $3,589,244 | $9,352,538 |
| Beginning Cash Position | $4,228,944 | $3,589,244 | $9,352,538 | $21,756 |
| Changes In Cash | $2,209,965 | $639,700 | $-5,763,294 | $9,330,782 |
| Proceeds From Stock Option Exercised | $2,783,412 | $5,914,922 | $1,872,739 | $0 |
| Net Issuance Payments Of Debt | $-109,482 | $-107,756 | $-56,366 | $146,250 |
| Net Long Term Debt Issuance | $-109,482 | $-107,756 | $-56,366 | $0 |
| Long Term Debt Payments | $-109,482 | $-107,756 | $-56,366 | $0 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-211,952 | $-178,403 |
| Purchase Of Intangibles | $0 | $0 | $-211,952 | $-178,403 |
| Net PPE Purchase And Sale | $-255,831 | $-603,890 | $-952,497 | $0 |
| Purchase Of PPE | $-255,831 | $-603,890 | $-952,497 | $0 |
| Change In Working Capital | $258,730 | $625,617 | $-1,269,935 | $-182,333 |
| Change In Payables And Accrued Expense | $-12,301 | $466,852 | $-572,246 | $33,942 |
| Change In Payable | $-12,301 | $466,852 | $-572,246 | $33,942 |
| Change In Account Payable | $-12,301 | $466,852 | $-572,246 | $33,942 |
| Change In Prepaid Assets | $176,805 | $-26,600 | $-231,307 | $-275,476 |
| Change In Inventory | $94,675 | $-34,292 | $-60,383 | $20,951 |
| Change In Receivables | $-449 | $219,657 | $-367,749 | $0 |
| Changes In Account Receivables | $-3,991 | $32,468 | $-149,906 | $0 |
| Other Non Cash Items | $51,875 | $45,600 | $115,503 | $20,000 |
| Stock Based Compensation | $130,409 | $365,309 | $1,011,973 | $1,734,601 |
| Asset Impairment Charge | $0 | $0 | $390,355 | $0 |
| Depreciation Amortization Depletion | $439,018 | $343,387 | $103,099 | $0 |
| Depreciation And Amortization | $439,018 | $343,387 | $103,099 | $0 |
| Depreciation | $439,018 | $343,387 | $103,099 | $0 |
| Net Foreign Currency Exchange Gain Loss | $-501,927 | $123,743 | $3,668 | $111 |
| Gain Loss On Sale Of PPE | $32,187 | $0 | $0 | - |
| Net Income From Continuing Operations | $-5,032,184 | $-6,067,232 | $-6,739,120 | $-5,457,763 |
| Issuance Of Debt | - | $0 | $0 | $487,500 |
| Net Short Term Debt Issuance | - | $0 | $-149,906 | $146,250 |
| Short Term Debt Payments | - | $0 | $-149,906 | $-341,250 |
| Short Term Debt Issuance | - | $0 | $0 | $487,500 |
| Change In Other Working Capital | - | - | $-38,250 | $38,250 |
Fetched: 2026-07-16